<DOC>
	<DOCNO>NCT00492869</DOCNO>
	<brief_summary>Efficacy safety AEB071 combination mycophenolate acid sodium , basiliximab steroid prevent acute rejection kidney transplantation .</brief_summary>
	<brief_title>Efficacy Safety AEB071 Versus Tacrolimus Combination With Mycophenolate Acid Sodium , Basiliximab Steroids Preventing Acute Rejection After Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion : Male female patient race 18 year old Adult recipient kidney transplant decease live donor Recipients function kidney within 24 hour post transplant Exclusion : Need medication prohibit protocol Patients donor infect Hepatitis B , C HIV Patients history cancer within last 5 year Patients history significant cardiac disorder Patients highrisk immunological status Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>kidney transplantation</keyword>
	<keyword>rejection</keyword>
	<keyword>AEB071</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>mycophenolic</keyword>
	<keyword>basiliximab</keyword>
	<keyword>immunosuppression</keyword>
</DOC>